Pharma Stock To Buy: Lincoln Pharmaceuticals Share Price Jumps 30% in 2026 So Far | Should You Buy?

Shares of Lincoln Pharmaceuticals Limited rallied during Thursday's intraday trading session. The Indian drugmaker is positioned to sustain a double-digit growth, supported by a diversified branded-generic portfolio, deepening penetration in high-margin chronic-therapy segments, etc, highlighted Angel One in its report.

Lincoln Pharmaceuticals stock was trading 2.15% higher at Rs 624.4 per share on BSE with a market capitalisation of Rs 1,250.66 crore at 3:15 pm. The stock had touched an intraday high of Rs 624.40 per share and an intraday low of Rs 615.30 per share.

Lincoln Pharmaceuticals Share Price Outlook

The firm is well-positioned to record a double-digit growth in the coming quarter. The management has targeted taking the overall revenue to Rs 1,000 crore in the next three years. The firm is likely to benefit from emerging key growth and margin lever.

"A near debt-free balance sheet with more than Rs. 200 crore of cash on balance sheet provides significant financial stability and the company is open for suitable growth opportunities including the potential for developing a greenfield manufacturing facility in Gujarat," noted Angel One in its report.

Lincoln Pharmaceuticals Share Price Recommendation

The brokerage gave a 'Buy' rating to the stock with a target price of Rs 845 per share. "We recommend a 'Buy' on LINCOLN with a target price of Rs. 845, valuing the stock at ~15x FY27E EPS of Rs. 56. A strong Q1 FY27 (PAT +31% YoY) leads us to lift our estimates, and the target is underpinned by a diversified branded-generic portfolio, a debt-free balance sheet, a widening regulated-market export franchise, and a credible path to Rs. 1,000 crore revenue. At ~14.5x trailing earnings, Lincoln trades at a steep discount to the ~30x pharma-sector median, leaving roomfor re-rating as earnings compound," stated the brokerage in its report.

Lincoln Pharmaceuticals Share Price Trend

The stock opened strong during Thursday's trading session. It touched its fresh 52-week high of Rs 770 per share on May 27, 2026. The stock dipped to its 52-week low of Rs 439.95 per share on January 28, 2026. It has a return on equity (ROE) of 15.09%. Its share price valuation has surged 30% in 2026 so far and around 92% in five years.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.